Conditions: Metastatic Colorectal Cancer
Keywords: Panitumumab Vectibix Colon Cancer Colorectal Cancer Rectal Cancer Cetuximab Erbitux Metastatic
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1010
Healthy volunteers: no

Brief summary:
The primary objective of this study is to compare the effect of panitumumab versus cetuximab on overall survival (OS) for chemorefractory metastatic colorectal cancer (mCRC) among patients with wild-type Kirsten rat Sarcoma-2 virus (KRAS) tumors.

Detailed description:

Arms:
arm 1: Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.

Participants were treated until disease progression, intolerability, withdrawal of consent, or death. arm 2: Panitumumab 6 mg/kg IV every 14 days. Participants were treated until disease progression, intolerability, withdrawal of consent, or death.

Interventions: intervention 1: Cetuximab intervention 2: Panitumumab
Intervention descriptions: intervention 1: Administered by intravenous infusion intervention 2: Administered by intravenous infusion

Protocol document: